Physician profile
Alan Stuart
NPI 1255893046
$3,320.10
in general payments reported to CMS, 2019-2025
23 companies · $755 in 2025
The $755 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $15.66 · 2023: $1,414 · 2024: $1,017 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,115.41 | 2021-2025 | |
| Axsome Therapeutics, INC. | $780.84 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.76 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $128.79 | 2023-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $120.13 | 2024 | |
| Supernus Pharmaceuticals, INC. | $118.47 | 2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $116.96 | 2023-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $80.34 | 2021-2025 | Rexulti |
| Tris Pharma INC | $73.07 | 2024-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $55.69 | 2024 | Pifeltro, Delstrigo |
| Viiv Healthcare Company | $51.82 | 2024 | Apretude |
| Theratechnologies INC. | $50.35 | 2024 | Trogarzo, Egrifta |
| Alkermes, INC. | $48.29 | 2023-2024 | Lybalvi, Aristada |
| Bausch Health US, LLC | $41.97 | 2024-2025 | Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.57 | 2024 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.07 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $32.34 | 2025 | Cobenfy |
| Lilly USA, LLC | $27.75 | 2024 | Mounjaro |
| Corium, LLC | $26.67 | 2023 | Azstarys |
| Novo Nordisk INC | $23.41 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $22.29 | 2024 | |
| Phathom Pharmaceuticals, INC. | $22.12 | 2024 | Voquezna |
| Ironshore Pharmaceuticals INC. | $16.99 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Stuart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.